Meet Jochi, the 2024 President’s Innovation Prize Winning Team Focused on Making Life Easier for Students with Learning Differences
The platform, called Jochi, which has further evolved since its conception in 2020, integrates easily into existing school systems and provides educators with tools to support these students.
EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
Exyn Technologies Partners with Measur to Expand Canadian Footprint
Measur plans to bring Exyn's cutting-edge technologies like the Nexys 3D SLAM LiDAR payload system to market.
Cogwear to Open New Manufacturing Facility in St. Paul as it Continues to Expand
This new site will support the production of Cogwear’s second-generation brain-tracking headband, which offers real-time insights into various brain functions.
EnaChip Leverages Magnetics to PowerNext-Generation Microdevices
By electroplating specialized magnetic alloys directly onto semiconductor substrates, EnaChip offers innovative, high-performance, and cost-effective magnetic solutions.
Ascidian Therapeutics Announces First-Ever FDA approval of their Investigational New Drug (IND) ACDN-01, which Targets Rare Genetic Eye Diseases
Penn spinout Ascidian Therapeutics has achieved a significant milestone with the FDA's acceptance of their Investigational New Drug (IND) application for ACDN-01.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.
Verismo Therapeutics Receives FDA Clearance for Phase I Trial of its CAR-T Therapy
Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.
iEcure Receives Three FDA Designations for its In Vivo Gene Insertion Program
iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.
Penn Startups Recognized in Labiotech’s List of “Eight companies spearheading Philadelphia’s biotech industry”
After emerging from stealth mode in 2023, BlueWhale aims to develop a technology platform and product portfolio that will provide the benefits of cell therapy to patients more quickly.